Novel targets for parkinsonism-depression comorbidity
Yousef Tizabi1, Bruk Getachew1, Antonei B Csoka2
1Department of Pharmacology, Howard University College of Medicine, Washington, DC, United States.
Progress in Molecular Biology and Translational Science
|October 12, 2019
Summary
This review explores the shared neurobiology of Parkinson's disease and depression, highlighting neuroplasticity as a key therapeutic target. Novel treatments focusing on neurotrophic and inflammatory factors offer hope for managing these interconnected conditions.
Area of Science:
- Neuroscience
- Psychiatry
- Gerontology
Background:
- Aging populations and rising neurodegenerative diseases present significant challenges.
- Psychiatric comorbidities, such as despair, exacerbate these conditions.
- Increasing understanding of neurobiology offers new therapeutic avenues.
Purpose of the Study:
- To review shared biological substrates between Parkinson's disease and depression.
- To suggest novel therapeutic targets and drugs for these conditions.
- To emphasize the role of neuroplasticity, neurotrophic, and inflammatory factors.
Main Methods:
- Literature review of shared biological substrates.
- Analysis of neuroplasticity mechanisms.
- Identification of potential therapeutic targets and drugs.
Main Results:
- Evidence suggests shared biological underpinnings between Parkinson's disease and depression.
- Neurotrophic and inflammatory factors play crucial roles in neuroplasticity.
- Several therapeutic drugs and future research directions are identified.
Conclusions:
- Targeting neuroplasticity holds promise for treating Parkinson's disease and depression.
- Further research into neurotrophic and inflammatory pathways is warranted.
- Integrated therapeutic approaches may improve patient outcomes.
Related Concept Videos
01:24Parkinson's Disease: Treatment
916
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
916
01:23Antidepressant Drugs: MAOIs and Other Agents
752
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
752
01:15Parkinson's Disease: Overview
1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
01:25Antidepressant Drugs: Overview
1.3K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.3K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K
01:22Alzheimer's Disease: Treatment
731
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
731